Arbutus Biopharma Corporation
NASDAQ:ABUS · NASDAQ Global Select
+$0.05 today
Vol 4.94M · Avg 1.76M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:ABUS · Revenue to Net Income
Key Ratios
Analysis
$191.4M of revenue converted into $160.7M of net income for the selected period. Gross margin is 99.2% and net margin is -425.7%, showing how much revenue survives after costs and taxes. EPS is $0.82, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14.1M +128.2% | $6.2M -66.0% | $18.1M -53.5% | $39.0M +255.1% | $11.0M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $363.0K | $0 | $0 | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | $13.7M +122.3% | $6.2M -66.0% | $18.1M -53.5% | $39.0M +255.1% | $11.0M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 97.4% -2.6pp | 100.0% +0.0pp | 100.0% +0.0pp | 100.0% +0.0pp | 100.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $25.2M -53.3% | $54.0M -26.7% | $73.7M -12.7% | $84.4M +28.9% | $65.5M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $15.9M -28.1% | $22.1M -1.6% | $22.5M +26.0% | $17.8M +4.1% | $17.1M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $40.8M -50.6% | $82.5M -14.3% | $96.2M -7.9% | $104.5M +23.6% | $84.5M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $363.0K -73.7% | $1.4M -1.7% | $1.4M -1.6% | $1.4M -18.6% | $1.8M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$33.0M +51.7% | -$68.4M +3.6% | -$71.0M -14.8% | -$61.9M +13.6% | -$71.6M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -234.6% +873.8pp | -1108.5% -717.2pp | -391.3% -232.8pp | -158.5% +493.4pp | -652.0% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$27.1M +64.6% | -$76.3M +2.3% | -$78.1M -19.3% | -$65.5M +11.0% | -$73.5M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -192.1% +1044.7pp | -1236.7% -806.2pp | -430.5% -262.8pp | -167.8% +501.4pp | -669.1% | 16.6% | 24.1% | 22.0% |
| Interest Income | $4.1M -38.2% | $6.6M +15.8% | $5.7M +159.5% | $2.2M +1626.0% | $127.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $97.0K -29.2% | $137.0K -70.2% | $459.0K -73.4% | $1.7M -39.6% | $2.9M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$6.5M -200.8% | $6.4M +21.8% | $5.3M +1083.3% | $444.0K +116.3% | -$2.7M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$33.5M +52.1% | -$69.9M +4.0% | -$72.8M -12.1% | -$65.0M +14.7% | -$76.2M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -237.9% +895.2pp | -1133.0% -731.5pp | -401.6% -235.0pp | -166.6% +527.3pp | -693.9% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 -100.0% | $4.4M | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$33.5M +52.1% | -$69.9M +4.0% | -$72.8M -4.9% | -$69.5M +8.9% | -$76.2M | $4.9B | $4.8B | $4.7B |
| Net Margin | -237.9% +895.2pp | -1133.0% -731.5pp | -401.6% -223.6pp | -178.0% +515.9pp | -693.9% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$0 +55.3% | -$0 +13.6% | -$0 +4.3% | -$0 +37.0% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$0 +55.3% | -$0 +13.6% | -$0 +4.3% | -$0 +37.0% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $191.6M +3.2% | $185.6M +11.8% | $166.0M +10.0% | $150.9M +42.1% | $106.2M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $191.6M +3.2% | $185.6M +11.8% | $166.0M +10.0% | $150.9M +42.1% | $106.2M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Tango Therapeutics, Inc.
NASDAQ:TNGX
$3.51B
Nanobiotix S.A.
NASDAQ:NBTX
$1.80B
Septerna, Inc.
NASDAQ:SEPN
$1.58B
GH Research PLC
NASDAQ:GHRS
$1.48B
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
$1.27B
EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
$1.13B
Savara Inc.
NASDAQ:SVRA
$1.11B
ARS Pharmaceuticals, Inc.
NASDAQ:SPRY
$951.33M
Kura Oncology, Inc.
NASDAQ:KURA
$857.03M
ProKidney Corp.
NASDAQ:PROK
$261.85M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does ABUS generate?
Arbutus Biopharma Corporation (ABUS) reported $14.08M of revenue in fiscal 2025.
Is ABUS profitable?
Arbutus Biopharma Corporation (ABUS) reported -$33,501,000.00 of net income, with a net margin of -237.9%.
Explore More
Continue the stock analysis
Jump to another research area for this company.